Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Abiraterone Acetate ◽

Androgen Deprivation ◽

What are the effects of abiraterone acetate as adjunct to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer?

Cochrane Clinical Answers ◽

10.1002/cca.3570 ◽

2021 ◽

Author(s):

Sera Tort ◽

Marta Briarava

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2017.12.012 ◽

2018 ◽

Vol 16 (2) ◽

pp. 130-134 ◽

Cited By ~ 8

Author(s):

Edoardo Francini ◽

Steven Yip ◽

Shubidito Ahmed ◽

Haocheng Li ◽

Luke Ardolino ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Outcomes ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Castration Resistant ◽

Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer (mHSPC): An updated network meta-analysis and cost minimization analysis in China.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e17008 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e17008-e17008

Author(s):

Xin Hu ◽

Xingxing Yao ◽

Chaoyun Li ◽

Yanjun Liu ◽

Tengbin Xiong ◽

...

Keyword(s):

Prostate Cancer ◽

Cost Minimization ◽

Meta Analysis ◽

High Volume ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Cost Minimization Analysis ◽

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Cochrane Database of Systematic Reviews ◽

10.1002/14651858.cd013245.pub2 ◽

2020 ◽

Author(s):

Niranjan J Sathianathen ◽

Makinna C Oestreich ◽

Sarah Jane Brown ◽

Shilpa Gupta ◽

Badrinath R Konety ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Benefit Of Abiraterone Acetate Plus Prednisone (AA+P) Added To Androgen Deprivation Therapy (ADT) In Patients With High-Risk, Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): Post Hoc Analysis Of EQ-5D-5L From The Latitude Study

Value in Health ◽

10.1016/j.jval.2018.04.317 ◽

2018 ◽

Vol 21 ◽

pp. S38 ◽

Cited By ~ 1

Author(s):

H Metin ◽

K McQuarrie ◽

P Thilakarathne ◽

J Diels ◽

T Ito ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Newly Diagnosed ◽

Post Hoc Analysis ◽

Hormone Sensitive ◽

Post Hoc

Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer

The Prostate ◽

10.1002/pros.24243 ◽

2021 ◽

Author(s):

Takafumi Yanagisawa ◽

Takahiro Kimura ◽

Keiichiro Mori ◽

Hirotaka Suzuki ◽

Takayuki Sano ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy

Current Medical Research and Opinion ◽

10.1080/03007995.2018.1447450 ◽

2018 ◽

Vol 34 (5) ◽

pp. 903-910 ◽

Cited By ~ 8

Author(s):

Loay Kassem ◽

Kyrillus S. Shohdy ◽

Omar Abdel-Rahman

Keyword(s):

Prostate Cancer ◽

Meta Analysis ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Safety And Efficacy ◽

Faculty Opinions recommendation of Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732006685.793538242 ◽

2017 ◽

Author(s):

Michael Glode

Keyword(s):

Prostate Cancer ◽

Systematic Review ◽

High Risk ◽

Meta Analysis ◽

Abiraterone Acetate ◽

Androgen Deprivation

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

European Urology ◽

10.1016/j.eururo.2021.05.016 ◽

2021 ◽

Author(s):

Christopher J. Sweeney ◽

Andrew J. Martin ◽

Martin R. Stockler ◽

Stephen Begbie ◽

Kim N. Chi ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Androgen Deprivation ◽

Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate

Prostate Cancer and Prostatic Diseases ◽

10.1038/s41391-021-00336-1 ◽

2021 ◽

Author(s):

Rosario F. Di Stefano ◽

Marcello Tucci ◽

Fabio Turco ◽

Alessandro Samuelly ◽

Maristella Bungaro ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Androgen Deprivation ◽

Castration Resistant Prostate Cancer ◽

Prognostic Role ◽

Castration Resistant ◽

Duration Of Response